Straits Times Index
3,318.41 +10.51 (+0.32%) Nikkei
39,103.22 +486.12 (+1.26%) Hang Seng
18,913.51 -282.09 (-1.47%) FTSE 100
8,360.34 -9.99 (-0.12%) Bitcoin USD
69,501.77 -99.64 (-0.14%) CMC Crypto 200
1,515.33 +12.67 (+0.84%)
Alkermes plc (8AK.F)
| Previous close | 22.00 |
| Open | 22.00 |
| Bid | 22.00 x N/A |
| Ask | 22.80 x N/A |
| Day's range | 22.00 - 22.00 |
| 52-week range | 20.15 - 29.80 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 3.774B |
| Beta (5Y monthly) | 0.58 |
| PE ratio (TTM) | 7.10 |
| EPS (TTM) | 3.10 |
| Earnings date | 22 Jul 2024 - 26 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 26.50 |
ZacksDo Options Traders Know Something About Alkermes (ALKS) Stock We Don't?
Investors need to pay close attention to About Alkermes (ALKS) stock based on the movements in the options market lately.
PR NewswireAlkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences
Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry franchise products—LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil)—at four scientific conferences this spring. These meetings take place during Mental Health Awareness Month in May, an important moment in the year to raise awareness about mental health conditions, support people living with these complex diseases, and honor the work of healthcare providers. The meetings
ZacksAlkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates
Alkermes' (ALKS) earnings and revenues miss first-quarter 2024 estimates. However, revenues rise year over year on strong proprietary product sales.
